Introduction
============

In general, the "target sign" on magnetic resonance imaging (MRI) is considered a pathognomonic finding for cerebral toxoplasmosis ([@B1], [@B2]). This target sign in cerebral toxoplasmosis has been shown to be divided into two findings: an "eccentric target sign" and a "concentric target sign". The "eccentric target sign" on contrast-enhanced T1-weighted imaging (CE-T1WI) has been considered highly suggestive of cerebral toxoplasmosis with 95% specificity, although this sign is observed in less than 30% of cases of cerebral toxoplasmosis ([@B1], [@B2]). More recently, the "concentric target sign" on T2-weighted imaging (T2WI), which has alternating concentric layers of T2-weighted hypo- and hyper-intensities, has been considered even more specific for cerebral toxoplasmosis ([@B3], [@B4]). However, in the daily clinical setting, it is often difficult to differentiate central nervous system (CNS) diseases that show a "target sign" on conventional MRI examinations, as "target signs" in cerebral toxoplasmosis, CNS lymphoma, primary and metastatic CNS tumors, and other intracranial infections, such as tuberculoma or abscesses, closely mimic each other ([@B4]).

Therefore, several studies have explored the utility of other diagnostic neuroimaging modalities to differentiate these diseases, such as ^201^Tl-single-photon emission computed tomography (^201^Tl-SPECT) ([@B5], [@B6]), ^18^F-fluorodeoxyglucose-positron emission tomography (^18^F-FDG PET) ([@B7]), and ^1^H-magnetic resonance spectroscopy (^1^H-MRS) ([@B8]). However, few studies have focused on the discrimination of these diseases, and the findings were not sufficiently conclusive.

We herein report a patient who was initially suspected of having cerebral toxoplasmosis based on a "target sign" on MRI and the absence of an abnormal accumulation on ^18^F-FDG PET. After ^201^Tl-SPECT revealed an abnormal accumulation, this patient was given a definitive diagnosis of brain metastasis from diffuse large B-cell lymphoma (DLBCL) based on a brain biopsy.

Case Report
===========

A 60-year-old man who had undergone eight cycles of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone chemotherapy because of a medical history of DLBCL presented with right hemiparesis (day 1). Images from ^18^F-FDG PET performed two weeks before the onset of the neurological symptoms showed increased metabolism only in the left supraclavicular fossa, with no increased ^18^F-FDG uptake in the brain. Contrast-enhanced 3D T1-weighted imaging \[CE-3D-T1WI; 3D fast-spoiled gradient-recalled echo acquisition in steady state (3D-SPGR), Signa Excite HD 3.0T; GE Medical Systems, (Milwaukee, USA)\] performed four days before the onset of the neurological symptoms showed ring enhancement with a small eccentric nodule in the left superior frontal gyrus, with edema ([Fig. 1A](#g001){ref-type="fig"}). This asymmetric lesion showed the "eccentric target sign" on CE-T1WI. The patient\'s right hemiparesis worsened, and he was admitted to our hospital on day 8.

![(A-C) Longitudinal "eccentric target sign" on contrast-enhanced 3D T1-weighted imaging (CE-3D-T1WI). Axial CE-3D-T1WI shows ring enhancement with a small eccentric nodule in the left superior frontal gyrus on imaging performed (A) four days before the onset of the neurological symptoms, (B) on day 11, and (C) on day 19. (D-H) Follow-up multimodal magnetic resonance study performed at admission and on day 11. (D) Diffusion-weighted imaging (***b***-value, 1,000 s/mm^2^) showing a high signal intensity in the surrounding wall. (E) Susceptibility-weighted imaging showing punctate hypo-intensities inside a mass lesion. (F) Arterial spin labeling cerebral blood flow maps showing a decreased signal intensity in the left frontal lesion. (G, H) ^1^H-magnetic resonance spectroscopy (MRS) was performed using the GE technique PROBE with PRESS. ^1^H-MRS showed a substantially reduced N-acetylaspartate (NAA) peak and an elevated choline (Cho) peak when a long echo time (TE) of 144 ms was used (G) and an elevated lipid (Lip) peak when a short echo time of 35 ms was used (H).](1349-7235-58-1157-g001){#g001}

The patient was alert and oriented, and his speech was clear and fluent. A neurological examination only revealed weakness, slightly brisk deep tendon reflexes without pathological reflexes in the upper and lower limbs on the right side (muscle bulk and tone were normal. Strength: deltoid 5/5, biceps 4/5, triceps 4/5, wrist extension 4/5, finger abduction 4/5, hip flexion 5/5, hip extension 5/5, knee flexion 4/5, knee extension 4/5, ankle flexion 4/5, ankle extension 4/5), and no signs of sensory disturbance. The white blood cell count was 2.71×10^3^/μL (CD4^+^ lymphocyte: 1,535/μL, CD8^+^ lymphocyte: 561/μL). Serum human immunodeficiency virus antibodies were negative. Anti-*Toxoplasma* IgG and IgM antibodies in the serum and cerebrospinal fluid (CSF) were negative. The levels of serum C-reactive protein, serum soluble interleukin-2 receptor (sIL-2R), and CSF sIL-2R were 0.10 mg/dL, 564 U/mL, and below 50 U/mL, respectively. CSF cytology revealed no evidence of malignant cells. A flow cytometric analysis and T-cell receptor gene and immunoglobulin heavy chain gene rearrangement analyses of the cells in CSF were not performed. Other laboratory data showed normal findings for blood and CSF.

Follow-up MRI was performed on day 11. CE-3D-T1WI showed enlargement of the lesion in the left frontal lobe ([Fig. 1B](#g001){ref-type="fig"}), and diffusion-weighted imaging showed high signal in the surrounding wall ([Fig. 1D](#g001){ref-type="fig"}). Susceptibility-weighted imaging (SWI) showed punctate hypo-intensities in the inside of a mass lesion ([Fig. 1E](#g001){ref-type="fig"}). Arterial spin labeling cerebral blood flow (CBF) maps showed a decreased signal intensity in the left frontal lesion ([Fig. 1F](#g001){ref-type="fig"}). ^1^H-MRS using a long echo time showed a reduced N-acetylaspartate peak and an elevated choline peak ([Fig. 1G](#g001){ref-type="fig"}), while with a short echo time, it showed an elevated lipid peak ([Fig. 1H](#g001){ref-type="fig"}). The lack of an increased uptake of ^18^F-FDG or increased CBF and the presence of the "eccentric target sign" on CE-T1WI, which is highly suggestive of cerebral toxoplasmosis, were findings atypical of malignant lymphoma. Thus, the patient was initially given a provisional diagnosis of cerebral toxoplasmosis and administered sulfamethoxazole/trimethoprim for seven days.

However, the MRI findings and clinical manifestations deteriorated despite treatment. ^201^Tl-SPECT performed on day 15 revealed a high radiotracer uptake in the lesion ([Fig. 2](#g002){ref-type="fig"}). Following this treatment, another MRI study was performed on day 19. CE-3D-T1WI showed thickening of the surrounding wall ([Fig. 1C](#g001){ref-type="fig"}, [3A](#g003){ref-type="fig"}) and an enhanced vessel entering a small papillary-shaped nodule located inward ([Fig. 3A](#g003){ref-type="fig"}). T2WI showed a mass lesion accompanied by multiple layers of varying intensity, i.e., the "concentric target sign" ([Fig. 3B](#g003){ref-type="fig"}). Nested-polymerase chain reaction (PCR) tests for *Toxoplasma gondii* 18S rDNA ([@B9]) in the CSF and peripheral blood were negative, and a serological analysis again revealed negative findings of IgG and IgM antibodies for *Toxoplasma*. On day 22, a brain biopsy revealed a metastatic brain tumor comprising DLBCL with large necrotic lesions ([Fig. 4](#g004){ref-type="fig"}). A nested-PCR test for *T. gondii* on the brain biopsy sample was also negative.

![^201^Tl-SPECT study performed on day 15. (A) Early ^201^Tl-SPECT imaging showing a high uptake of radioactivity in the lesion. (B) Delayed ^201^Tl-SPECT imaging showing a slightly lower uptake of radioactivity in the same area as in (A). Retention index=0.9.](1349-7235-58-1157-g002){#g002}

![Follow-up MRI performed on day 19. (A) Coronal CE-3D-T1WI showing a thickened surrounding wall and small papillary-shaped nodule with gadolinium enhancement located inward. (B) Coronal T2WI showing the appearance of multiple layers of alternate hyper-, iso-, and hypo-intensities (i.e., the concentric target sign).](1349-7235-58-1157-g003){#g003}

![Histological and immunohistochemical findings from the frontal lobe biopsy. (A) Diffuse proliferation of atypical lymphocytes is present \[Hematoxylin and Eosin (H&E) staining\]. (B) The tumor cells are large with hyperchromatic nuclei and scant cytoplasm (H&E staining). (C) The atypical cells are negative for CD3 (Immunohistochemical staining). (D) The atypical cells are positive for CD10 (Immunohistochemical staining). (E) The atypical cells are positive for CD20 (Immunohistochemical staining). (F) Ki-67 labeling index is more than 90% (Immunohistochemical staining). (G) Broad areas of necrosis are visible (H&E staining). Scale bars: 250 μm (A, F, G); 100 μm (B-E).](1349-7235-58-1157-g004){#g004}

The patient\'s conditions partly improved after high-dose methotrexate with rituximab and radiation therapies.

Discussion
==========

Positive findings of serological IgM and IgG antibodies and PCR for *T. gondii* in peripheral blood, serum, and CSF samples have a high specificity for the diagnosis of toxoplasmosis ([@B10]). However, the accurate diagnosis of acute cerebral toxoplasmosis is often difficult without positive laboratory findings. Porter et al. ([@B11]) reported that 20% cases of AIDS-related CNS toxoplasmosis were seronegative for *Toxoplasma*. As the serological test for *T. gondii* was negative in this case, it was difficult to diagnose.

When serological and CSF tests show negative findings for *Toxoplasma*, several imaging studies are relied upon for the diagnosis. Regarding toxoplasmosis, two features are considered to be pathognomonic: the "eccentric target sign" on CE-T1WI and the "concentric target sign" on T2WI. The central enhancing core of the "eccentric target sign" seen on CE-T1WI is produced by a thickened vessel traversing a sulcus. The peripheral enhancing rim is produced by a wall composed of histiocytes and proliferating blood vessels with impaired permeability ([@B2]). The "concentric target sign" on T2WI is a recently described indication of cerebral toxoplasmosis and more specific for toxoplasmosis ([@B3], [@B4]) than tuberculoma ([@B4]). It consists of concentric alternating zones of hypo-, hyper-, and iso-intensities. It is thought that T2 hypo-, hyper-, and iso-intensities correspond to zones of hemorrhaging, fibrin-rich necrosis with edema, and compact coagulative necrosis, respectively ([@B4]). In cerebral tuberculomas, the "target sign" on T2WI has been reported to be consisted of two zones with hypo-/hyper- intensities and was extremely rare ([@B12], [@B13]). Wasay et al. reported that target-like lesions were seen in only 2% of 100 cases with intracranial tuberculoma ([@B14]). In Baló\'s concentric sclerosis, one or more concentrically multilayered lesions are shown ([@B15]). In our case, the findings on other MRI modalities and radioisotope examinations provided little evidence of Baló\'s concentric sclerosis. Our present case showed hemorrhaging and extensive necrosis on SWI and histopathology, respectively. These findings can be seen in both lymphoma and toxoplasmosis and might have reflected the rapid disease progression. In fact, our present patient was afflicted with metastatic lymphoma, not toxoplasmosis. These results indicate that the MRI findings for metastatic lymphoma can also show an appearance similar to the "concentric target sign" on T2WI of toxoplasmosis.

In situations where it is difficult to differentiate intracranial neoplasms such as lymphoma from non-neoplastic diseases such as toxoplasmosis on MRI, a combination of various imaging modalities should be used to perform a differential diagnosis. Several studies have evaluated the use of ^201^Tl-SPECT for this purpose ([@B5], [@B6]); an increased focal ^201^Tl uptake suggests lymphoma, and no ^201^Tl uptake in the lesion suggests toxoplasmosis. However, Licho et al. reported that the sensitivity and specificity of ^201^Tl-SPECT for lymphoma are 60% and 55%, respectively, with an accuracy of 57% ([@B16]). Thus, in some cases, ^201^Tl-SPECT may be unreliable for differentiating lymphoma from non-lymphoma. The case described here showed the uptake of ^201^Tl, which led to the decision to perform a brain biopsy.

Primary CNS lymphoma shows a very high cellular density and increased glucose metabolism and usually shows a strong uptake of ^18^F-FDG in the tumor. In contrast, Rohren et al. reported that only 61% of cerebral metastatic lesions found on MRI were detected on ^18^F-FDG-PET ([@B17]). Size was a statistically significant factor influencing lesion detection on PET. The average diameter of MRI-detected lesions that went undetected on PET was 0.7 cm (range, 0.2-1.3 cm) ([@B17]). In our case, ^18^F-FDG-PET was performed before the onset of neurological symptoms with negative findings. Therefore, the cerebral lesion might have been too small to detect. Follow-up ^18^F-FDG-PET was not performed after the onset of the neurological symptoms.

Differentiating lymphoma from non-neoplastic lesions can be difficult, as both conditions may appear clinically and radiologically similar. Studies including a large series of cases and the development of a novel neuroimaging modality for the differential diagnosis are needed to obviate the need for a brain biopsy.
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